Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
Noosa News23 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News23 hours agoE-biker charged with riding dangerously, assaulting cop
-
General22 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Business16 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today